GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MedMira Inc (OTCPK:MMIRF) » Definitions » Profitability Rank

MedMira (MedMira) Profitability Rank : 0 (As of Jan. 2024)


View and export this data going back to . Start your Free Trial

What is MedMira Profitability Rank?

MedMira has the Profitability Rank of 0.

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:

1. Operating Margin %
2. Piotroski F-Score
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank

MedMira's Operating Margin % for the quarter that ended in Jan. 2024 was -246.85%. As of today, MedMira's Piotroski F-Score is 3.


Competitive Comparison of MedMira's Profitability Rank

For the Biotechnology subindustry, MedMira's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MedMira's Profitability Rank Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MedMira's Profitability Rank distribution charts can be found below:

* The bar in red indicates where MedMira's Profitability Rank falls into.



MedMira Profitability Rank Calculation

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

MedMira has the Profitability Rank of 0.

Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.

Profitability Rank is based on these factors:

1. Operating Margin %

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

MedMira's Operating Margin % for the quarter that ended in Jan. 2024 is calculated as:

Operating Margin %=Operating Income (Q: Jan. 2024 ) / Revenue (Q: Jan. 2024 )
=-0.274 / 0.111
=-246.85 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

2. Piotroski F-Score

Warning Sign:

Piotroski F-Score of 3 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 8 or 9
Bad or low score = 0 or 1

MedMira has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.

4. Consistency of the profitability

5. Predictability Rank


MedMira Profitability Rank Related Terms

Thank you for viewing the detailed overview of MedMira's Profitability Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


MedMira (MedMira) Business Description

Traded in Other Exchanges
Address
155 Chain Lake Drive, Suite 1, Halifax, NS, CAN, B3S 1B3
MedMira Inc is a biotechnology company that is engaged in the business of research, development, and manufacturing of rapid diagnostics and technologies. The company has one reportable operating segment, rapid diagnostic products and services. The product line of the company includes RevealHIV which detects antibodies to HIV-1 and HIV-2 in whole blood, serum or plasma; H Pylori which detects antibodies in serum, plasma, and whole blood; syphilis which detects treponema pallidum antibodies in serum, plasma, and whole blood; among other products. The company generates revenue geographically from North America, Europe, Asia pacific. The majority of the revenue is generated from North America.

MedMira (MedMira) Headlines

From GuruFocus

Progress Update on Securities

By ACCESSWIRE 08-31-2023

Progress Update on MedMira's COVID-19 Product Family

By GlobeNewswire GlobeNewswire 01-30-2021

MedMira Reports 2019 Fourth Quarter and Year End Financial Results

By GlobeNewswire GlobeNewswire 11-29-2019

MedMira Introduces VYRA TriDemic

By ACCESSWIRE ACCESSWIRE 12-30-2022

MedMira Reports Third Quarter Results FY2022

By GlobeNewswire GlobeNewswire 06-30-2022

Management Cease Trade Order Update

By GlobeNewswire GlobeNewswire 12-26-2018

MedMira Reports Third Quarter Results FY2021

By GlobeNewswire GlobeNewswire 06-30-2021

MedMira Reports First Quarter Results FY2022

By GlobeNewswire GlobeNewswire 12-31-2021

MedMira Announces Product Update

By GlobeNewswire GlobeNewswire 12-31-2020

MedMira receives CE mark for its VYRA(TM) CoV2Flu Antigen Test

By ACCESSWIRE ACCESSWIRE 01-11-2023